Gene therapy studies, which began in the early 1980's, have now reached the point where critical importance of basic studies into the diseases and the biology associated with gene transfer have become widely acknowledged. In particular, studies on hemophilia B (factor IX deficiency) have greatly contributed to the understanding of gene transfer biology in general and have highlighted specific issues which must be systematically studied before safe and truly robust clinical human gene therapies can be developed. To date, most of these fundamental issues remain to be addressed. The studies detailed in this proposal will continue to focus study on hemophilia B by vigorously addressing selected critical issues and gaining insights into the basic biology underlying gene transfer. Studies proposed have three major aims centered on factor IX (FIX) as the model gene:
Aim 1, delineation of the biology and mechanisms involved in muscle- targeted gene transfer;
Aim 2, development of a robust FIX AAV (adeno-associated virus) - mediated gene transfer system;
Aim 3, characterization of the immune responses to IX, delivered as a purified protein and by gene transfer approaches, and development of methods for induces immune tolerance. Establishment of an extensively studied and mechanistically well- understood gene therapy for hemophilia B will serve as a model for future gene therapy studies, and will provide an exciting foundation for development of clinical therapies, not only for hematological and metabolic diseases requiring systemic or local delivery of gene products, but also for other diseases such as muscular disorders.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL053713-06
Application #
6052053
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1994-09-30
Project End
2004-01-31
Budget Start
2000-02-01
Budget End
2001-01-31
Support Year
6
Fiscal Year
2000
Total Cost
$340,669
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Genetics
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Kolka, Jacquelyn A; Vreede, Andrew P; Roessler, Blake J (2005) Lipopolysaccharide recognition protein, MD-2, facilitates cellular uptake of E. coli-derived plasmid DNA in synovium. J Gene Med 7:956-64
Allen, David L; Teitelbaum, Daniel H; Kurachi, Kotoku (2003) Growth factor stimulation of matrix metalloproteinase expression and myoblast migration and invasion in vitro. Am J Physiol Cell Physiol 284:C805-15
Krebsbach, Paul H; Zhang, Kezhong; Malik, Ajay K et al. (2003) Bone marrow stromal cells as a genetic platform for systemic delivery of therapeutic proteins in vivo: human factor IX model. J Gene Med 5:11-7
Malik, A K; Wang, J M; Kurachi, K (2001) Effects of a second intron on recombinant MFG retroviral vector. Arch Virol 146:601-9
Kurachi, K; Kurachi, S (2000) Genetic mechanisms of age regulation of blood coagulation: factor IX model. Arterioscler Thromb Vasc Biol 20:902-6
Livant, D L; Brabec, R K; Pienta, K J et al. (2000) Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res 60:309-20
Kurachi, K; Zhang, K; Ameri, A et al. (2000) Genetic and molecular mechanisms of age regulation (homeostasis) of blood coagulation. IUBMB Life 49:189-96
Malik, A K; Monahan, P E; Allen, D L et al. (2000) Kinetics of recombinant adeno-associated virus-mediated gene transfer. J Virol 74:3555-65
Livant, D L; Brabec, R K; Kurachi, K et al. (2000) The PHSRN sequence induces extracellular matrix invasion and accelerates wound healing in obese diabetic mice. J Clin Invest 105:1537-45
Brooks, M (1999) A review of canine inherited bleeding disorders: biochemical and molecular strategies for disease characterization and carrier detection. J Hered 90:112-8

Showing the most recent 10 out of 20 publications